MG
ALNY icon

Marex Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Marex Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$662K Buy
+2,000
New +$681K ﹤0.01% 546
2025
Q2 		– Sell
-1,173
Closed -$317K – 653
2025
Q1 		$317K Sell
1,173
-95
-7% -$24.4K 0.01% 441
2024
Q4 		$298K Buy
+1,268
New +$333K 0.01% 451
2023
Q3 		– Sell
-1,334
Closed -$253K – 217
2023
Q2 		$253K Sell
1,334
-239
-15% -$47.4K 0.05% 182
2023
Q1 		$315K Buy
1,573
+581
+59% +$122K 0.04% 198
2022
Q4 		$236K Buy
+992
New +$212K 0.03% 216

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marex Group's ALNY Position: Q1 2026 in Review

Marex Group opened a new position in Alnylam Pharmaceuticals (ALNY) in Q1 2026: 2,000 shares worth $662K. The stake represents ﹤0.01% of the portfolio and ranks #546 among its holdings. This is a return to the name: Marex Group previously reported a position in ALNY as recently as Q1 2025.

Marex Group first reported a position in ALNY in Q4 2022 and has held it in 6 quarters since. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Marex Group held 2,000 shares of Alnylam Pharmaceuticals worth $662K as of Q1 2026.
  • Alnylam Pharmaceuticals was a new Marex Group position in Q1 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Marex Group's portfolio in Q1 2026, its #546 holding.
  • Marex Group first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 6 quarters since.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.